Proteomics

Proteomics

Global Proteomics Market to Reach US$66.7 Billion by 2030

The global market for Proteomics estimated at US$34.1 Billion in the year 2023, is expected to reach US$66.7 Billion by 2030, growing at a CAGR of 10.1% over the analysis period 2023-2030. Proteomics Reagents, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$49.2 Billion by the end of the analysis period. Growth in the Proteomics Instruments segment is estimated at 10.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.6 Billion While China is Forecast to Grow at 12.7% CAGR

The Proteomics market in the U.S. is estimated at US$12.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Global Proteomics Market - Key Trends & Drivers Summarized

Proteomics is the large-scale study of proteins, their structures, functions, and interactions within a biological system. As proteins are essential to nearly every cellular process, proteomics provides crucial insights into how cells function and how diseases develop. Techniques used in proteomics include mass spectrometry, protein microarrays, and various bioinformatics tools to identify and quantify proteins, analyze protein modifications, and map protein-protein interactions. These techniques allow scientists to explore the proteome, the entire set of proteins produced by an organism, tissue, or cell. By comparing proteomes under different conditions, researchers can identify disease biomarkers, understand disease mechanisms, and develop targeted therapies, making proteomics indispensable in biomedical research.

Recent advancements in proteomics have significantly enhanced its capabilities and applications. High-resolution mass spectrometry and advanced bioinformatics tools have improved the accuracy and efficiency of protein identification and quantification. Innovations such as next-generation sequencing and CRISPR technology have facilitated the integration of proteomics with genomics and transcriptomics, providing a more comprehensive understanding of cellular processes. Additionally, the development of single-cell proteomics is opening new avenues for studying cellular heterogeneity and disease progression at an unprecedented resolution. These technological advancements are driving the adoption of proteomics in various fields, including drug discovery, personalized medicine, and clinical diagnostics, as they enable more precise and detailed analysis of the proteome.

The growth in the proteomics market is driven by several factors. The increasing prevalence of chronic diseases such as cancer and cardiovascular diseases has heightened the demand for advanced diagnostic and therapeutic solutions, spurring the adoption of proteomics. The shift towards personalized medicine, which relies on understanding individual proteomic profiles to tailor treatments, is also a significant driver. Factors supporting growth also include development of protein targeted treatments and precision molecular medicines for many autoimmune diseases, development of mass spectrometry-based proteomics, and development of molecular targets in malignancies. Increasing focus of biotechnological and pharmaceutical companies in research and development for identifying new proteomics applications, development of new drugs, and proteomics biomarker discovery in different types of diseases such as cardiovascular diseases and cancer is the major trend in the global proteomics landscape. Technological advancements in mass spectrometry and bioinformatics are enhancing the capabilities of proteomic analysis, making it more accessible and cost-effective. Furthermore, the expansion of research in areas such as biomarker discovery and drug development is fueling market growth. Government and private sector investments in proteomics research and infrastructure, coupled with collaborations between academic institutions and pharmaceutical companies, are also contributing to the market`s expansion. These factors, along with the growing recognition of proteomics as a critical tool in life sciences research, are propelling the growth of the proteomics market.

Select Competitors (Total 178 Featured) -

• Active Motif, Inc.
• 20/20 Genesystems, Inc.
• BG Medicine, Inc.
• BGI-Shenzhen
• Biodesix, Inc.
• Abbiotec LLC
• BioChain Institute, Inc.
• Arbor Vita Corporation
• Biomosaics, Inc.
• Advansta Inc.
• AYOXXA Biosystems GmbH
• AKESOgen, Inc.
• Biognosys
• Biorbyt
• BioAnalyte

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.